Aravive Forecasted Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Aravive.
Earnings growth rate
EPS growth rate
|Biotechs earnings growth||16.4%|
|Revenue growth rate||-32.3%|
|Future return on equity||n/a|
|Last updated||22 Aug 2023|
Recent future growth updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash WiselyApr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash WiselySep 03
Aravive Q2 GAAP EPS misses, revenue beatsAug 11
Aravive appoints Robert Geller as CMOJul 05
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth CarefullyMay 15
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In GrowthNov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In GrowthJun 25
Aravive EPS beats by $0.01, misses on revenueMay 06
Aravive shares rise after dosing first patient in late-stage ovarian cancer studyApr 27
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?Mar 18
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In GrowthFeb 09
Aravive: Pipeline-In-A-Pill In OncologyDec 28
Aravive (ARAV) Investor Presentation - SlideshowDec 04
Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiativeNov 19
Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater ChinaNov 10
Earnings and Revenue Growth Forecasts
|Date||Revenue||Earnings||Free Cash Flow||Cash from Op||Avg. No. Analysts|
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARAV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARAV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARAV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARAV's revenue is expected to decline over the next 3 years (-32.3% per year).
High Growth Revenue: ARAV's revenue is forecast to decline over the next 3 years (-32.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARAV's Return on Equity is forecast to be high in 3 years time